Increased Expression of Tumor Proliferation Genes in Hispanic Women with Early-Stage Breast Cancer

REFERENCES

• Siegel R, Naishadham D, Jemal A. Cancer statistics for Hispanics/Latinos, 2012. CA: A Cancer J Clin 2012;62(5):283–298.
   PubMed Web of Science ®Google Scholar
• Frost F, Tollestrup K, Hunt WC, Gilliland F, Key CR, Urbina CE. Breast cancer survival among New Mexico Hispanic, American Indian, and non-Hispanic white women (1973–1992). Cancer Epidem Biomar & Prevention 1996;5(11):861–866.
   PubMed Web of Science ®Google Scholar
• Li CI, Malone KE, Daling JR. DIfferences in breast cancer stage, treatment, and survival by race and ethnicity. Arch Intern Med 2003;163(1):49–56.
   PubMed Web of Science ®Google Scholar
• Elledge RM, Clark GM, Chamness GC, Osborne CK. Tumor Biologic Factors and Breast Cancer Prognosis Among White, Hispanic, and Black Women in the United States. J Natl Cancer I 1994;86(9):705–712.
   PubMed Web of Science ®Google Scholar
• Ooi S, Martinez M, Li C. Disparities in breast cancer characteristics and outcomes by race/ethnicity. Breast Cancer Res Tr 2011;127(3):729–738.
   PubMed Web of Science ®Google Scholar
• Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller HT, Fisher ER, Wickerham DL, Bryant J, Wolmark N. A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer. New Engl J Med 2004;351(27):2817–2826.
   PubMed Web of Science ®Google Scholar
• Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE, Wickerham DL, Wolmark, N. Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer. J Clin Oncol 2006;24(23): 3726–3734.
   PubMed Web of Science ®Google Scholar
• Albain KS, Bralow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborne CK, Hayes DF. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. The Lancet Oncol 2010;11(1):55–65.
   PubMed Web of Science ®Google Scholar
• Dowsett M, Cuzick J, Wale C, Forbes J, Mallon EA, Salter J, Quinn E, Dunbier A, Baum M, Buzdar A, Howell A, Bugarini R, Baehner FL, Shak S. Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study. J Clin Oncol 2010;28(11):1829–1834.
   PubMed Web of Science ®Google Scholar
• Albain KS, Barlow WE, Shak S, Hortobagyi GN, Hayes DF. Potential biologic causes of the racial survival disparity in adjuvant trials of ER-positive breast cancer. Journal of Clinical Oncology 28:15s, 2010 (supplement; abstract 511).
   Google Scholar
• Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FCG, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Whittliff JL, Wolff AC. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. J Clin Oncol 2010;28(16):2784–2795.
   PubMed Web of Science ®Google Scholar
• Hammond ME, Hayes DF, Wolff AC. Clinical Notice for American Society of Clinical Oncology-College of American Pathologists Guideline Recommendations on ER/PgR and HER2 Testing in Breast Cancer. J Clin Oncol 2011;29(15):e458.
   PubMed Web of Science ®Google Scholar
• Collecchi P, Santoni T, Gnesi E, Giuseppe Naccarato A, Passoni A, Rocchetta M, Danesi R, Bevilacqua G. Cyclins of phases G1, S and G2/M are overexpressed in aneuploid mammary carcinomas. Cytometry 2000;42(4):254–260.
   PubMedGoogle Scholar
• Ouchi M, Fujiuchi N, Sasai K, Katayama H, Minamishima YA, Ongusaha PP, Deng C, Sen S, Lee SW, Ouchi T. BRCA1 Phosphorylation by Aurora-A in the Regulation of G2 to M Transition. J Biol Chem 2004;279(19):19643–19648.
   PubMed Web of Science ®Google Scholar
• Siggelkow W, Boehm D, Gebhard S, Battista M, Sicking I, Lebrecht A, Solbach C, Hellwig B, Rahnenführer J, Koelbl H, Gehrmann M, Marchan R, Cadenas C, Hengstler JG, Schmidt M. Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients. BMC Cancer 2012;12(1):562.
   PubMedGoogle Scholar
• Diamond JR, Eckhardt SG, Tan AC, Newton TP, Selby HM, Brunkow KL, Kachaeva MI, Varella-Garcia M, Pitts TM, Bray MR, Fletcher GC, Tentler JJ. Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models. Clin Cancer Res 2013;19(1): 291–303.
   PubMed Web of Science ®Google Scholar
• Fiskus W, Hembruff S, Rao R, Sharma P, Balusu R, Venkannagari S, Smith JE, Peth K, Peiper SC, Bhalla K. Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells. Breast Cancer Res Tr 2012;135(2):433–444.
   PubMed Web of Science ®Google Scholar
• Jani JP, Arcari J, Bernardo V, Bhattacharya SK, Briere D, Cohen BD, Coleman K, Christensen JG, Emerson EO, Jakowski A, Hook K, Los G, Moyer JD, Pruimboom-Brees I, Pustilnik L, Rossi AM, Steyn SJ, Su C, Tsaparikos K, Wishka D, Yoon K, Jakubczak JL. PF-03814735, an Orally Bioavailable Small Molecule Aurora Kinase Inhibitor for Cancer Therapy. Mol Cancer Ther 2010;9(4):883–894.
   PubMed Web of Science ®Google Scholar
• Roberts PJ, Bisi JE, Strum JC, Combest AJ, Darr DB, Usary JE, Zamboni WC, Wong KK, Perou CM, Sharpless NE. Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy. J Natl Cancer I 2012;104(6):476–487.
   PubMed Web of Science ®Google Scholar
• Dean JL, McClendon AK, Hickey TE, Butler LM, Tilley WD, Witkiewicz AK, Knudsen ES. Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell Cycle 2012;11(14):2756–2761.
   PubMed Web of Science ®Google Scholar
• Wang Y, Beydoun MA. Obesity Epidemic in the United States—Gender, Age, Socioeconomic, Racial/Ethnic, and Geographic Characteristics: A Systematic Review and Meta-Regression Analysis. Epidemiol Rev 2007;29(1):6–28.
   PubMed Web of Science ®Google Scholar
• Cowie CC, Rust KF, Byrd-Holt DD, Eberhardt MS, Flegal KM, Engelgau MM, Saydah SH, Williams DE, Gleiss LS, Gregg EW. Prevalence of Diabetes and Impaired Fasting Glucose in Adults in the U.S. Population: National Health and Nutrition Examination Survey 1999–2002. Diab Care 2006;29(6):1263–1268.
   PubMed Web of Science ®Google Scholar
• Protani M, Coory M, Martin J. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Tr 2010;123(3):627–635.
   PubMed Web of Science ®Google Scholar
• Sparano JA, Wang M, Zhao F, Stearns V, Martino S, Ligibel JA, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Fetting J, Davidson NE. Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer 2012;118(23):5937–5946.
   PubMed Web of Science ®Google Scholar
• Kamineni A, Anderson M, White E, Taplin SH, Porter P, Ballard-Barbash R, Malone K, Buist DM. Body mass index, tumor characteristics, and prognosis following diagnosis of early-stage breast cancer in a mammographically screened population. Cancer Caus Control 2013;24(2):305–312.
   PubMed Web of Science ®Google Scholar
• Daling JR, Malone KE, Doody DR, Johnson LG, Gralow JR, Porter PL. Relation of body mass index to tumor markers and survival among young women with invasive ductal breast carcinoma. Cancer 2001;92(4):720–729.
   PubMed Web of Science ®Google Scholar
• Williams DJ, Cohen C, Darrow M, Page AJ, Chastain B, Adams AL. Proliferation (Ki-67 and phosphohistone H3) and oncotype DX recurrence score in estrogen receptor-positive breast cancer. Appl Immunohistochem Mol Morphol 2011;19(5):431–436.
   PubMedGoogle Scholar
• Sahebjam S, Aloyz R, Pilavdzic D, Brisson ML, Ferrario C, Bouganim N, Bouganim N, Cohen V, Miller WH, Panasci LC. Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score. Br J Cancer 2011;105(9):1342–1345.
   PubMed Web of Science ®Google Scholar
• Weiss SE, Tartter PI, Ahmed S, Brower ST, Brusco C, Bossolt K, Amberson JB, Bratton J. Ethnic differences in risk and prognostic factors for breast cancer. Cancer 1995;76(2):268–74.
   PubMed Web of Science ®Google Scholar
• Colozza M, Sidoni A, Piccart-Gebhart M. Value of Ki67 in breast cancer: the debate is still open. Lancet Oncol 2010;11(5):414–415.
   PubMed Web of Science ®Google Scholar
• Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 2010;11(2):174–183.
   PubMed Web of Science ®Google Scholar